BTIG Initiates Coverage On Tiziana Life Sciences with Buy Rating, Announces Price Target of $7

Benzinga Newsdesk www.benzinga.com Positive 55.2%

Neg 0% Neu 0% Pos 55.2%

BTIG analyst Thomas Shrader initiates coverage on Tiziana Life Sciences (NASDAQ:TLSA) with a Buy rating and announces Price Target of $7.